跳至主要内容
临床试验/IRCT20130812014333N145
IRCT20130812014333N145招募中3 期

Comparative assessment of the efficacy and safety of add ontreatment with Sofosbuvir plus Velpatasvir” to standard of care therapeutic regimen” in patients with COVID-19

Kermanshah University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Age over 18 years
  • Absolute lymphocyte count <1100 / ML or SaO2 <93

排除标准

  • Pregnancy or breast-feeding
  • The physician's decision that the trial is not in the patient's interest
  • Any circumstances that do not allow to follow the treatment protocol easily
  • A history of severe liver disease including cirrhosis or ALT or AST levels more than fives times normal
  • Drugs that are contraindicated with standard treatment or Sofosbuvir-Velpatasvir and cannot be discontinued
  • History of untreated HIV infection or hepatitis C

研究者

相似试验